Ticlopidine Inhibits the Prothrombotic Effects of Thrombopoietin and Ameliorates Survival after Supralethal Total Body Irradiation

Summary

Thrombopoietin modulates the response of platelets to several agonists and, on the other hand, those agonists can be released following irradiation. Thus, we have determined the effects of thrombopoietin, on its own and in combination with ticlopidine, an anti-platelet drug, on platelet activation, thrombosis formation and survival of irradiated C57BL6/J mice. Administration of thrombopoietin 2 h after 9 Gy total body irradiation increased the ¹²⁵I-fibrin deposition in mouse tissues and accelerated platelet consumption as revealed by an enhanced drop in platelet counts. Additionally, the number of activated platelets, i.e. those expressing P-selectin on their membrane, was higher in thrombopoietin-treated mice as compared to the placebo group, regardless ex vivo stimulation with agonists. These effects of thrombo-poietin on platelet activation and consumption were reduced when mice were pretreated with ticlopidine. The combination of ticlopidine with thrombopoietin almost fully promoted 180-day survival, reaching the same efficacy as bone marrow transplantation, while only 30% of the mice treated with thrombopoietin alone survived. In summary, thrombopoietin induces long term-mortality of irradiated mice probably through platelet-mediated thrombosis and thus, ticlopidine efficiently counteracts these adverse effects of thrombopoietin.

Keywords

Thrombopoietin - irradiation - thrombosis - platelet - ticlopidine

• References

• 1 Phillips TL. An ultrastructural study of the development of radiation injury in the lung. Radiology 1966; 87: 49-54.
• 2 Fike JR, Cann CE, Davis RL, Borcich JK, Phillips TL, Russell LB. Computed tomography analysis of the canine brain: effects of hemibrain X irradiation. Radiat Res 1984; 99: 294-310.
• 3 Call GK, Bray PF, Smoker WR, Buys SS, Hayes JK. Carotid thrombosis following neck irradiation. Int J Radiat Oncol Biol Phys 1990; 18: 635-40.
• 4 Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994; 14: 495-504.
• 5 Robbins ME, Stephens LC, Johnston DA, Thames HD, Peters LJ, Hopewell JW, Ang KK. A morphometric analysis of glomerular and tubular alterations following fast-neutron irradiation of the pig and monkey kidney. Int J Radiat Oncol Biol Phys 1998; 41: 1149-56.
• 6 Bergstein J, Andreoli SP, Provisor AJ, Yum M. Radiation nephritis following total-body irradiation and cyclophosphamide in preparation for bone marrow transplantation. Transplantation 1986; 41: 63-6.
• 7 Rahmouni A, Montazel JL, Golli M, Anglade MC, Berger JF, Vasile N, Mathieu D. Unusual complication of liver irradiation: acute thrombosis of a main hepatic vein: CT and MR imaging features. Radiat Med 1992; 10: 163-6.
• 8 Verheij M, Dewit LGH, van Mourik JA. The effect of ionizing radiation on endothelial tissue factor activity and its cellular localization [letter]. Thromb Haemost 1995; 73: 894-5.
• 9 Richter KK, Fink LM, Hughes BM, Sung CC, Hauer-Jensen M. Is the loss of endothelial thrombomodulin involved in the mechanism of chronicity in late radiation enteropathy?. Radiother Oncol 1997; 44: 65-71.
• 10 Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1997; 89: 2429-42.
• 11 Sporn LA, Rubin P, Marder VJ, Wagner DD. Irradiation induces release of von Willebrand protein from endothelial cells in culture. Blood 1984; 64: 567-70.
• 12 Verheij M, Dewit LGH, Boomgaard MN, Brinkman HJM, Van Mourik JA. Ionizing radiation enhances platelet adhesion to the extracellular matrix of human endothelial cells by an increase in the release of von willebrand factor. Radiat Res 1994; 137: 202-7.
• 13 Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemost 1991; 65: 467-73.
• 14 Kalovidouris AE, Papayannis AG. Effect of ionizing radiation on platelet function in vitro. Acta Radiol Oncol 1981; 20: 333-6.
• 15 Navratil L, Pospisil J, Blehova Z. Changes of 6-keto PGF1 alpha concentration in plasma and vessel wall and TxB2 in plasma of whole-body irradiated rats in the early stage of irradiation. Prostaglandins Leukot Essent Fatty Acids 1990; 41: 39-43.
• 16 Eldor A, Vlodavsky I, HyAm E, Atzmon R, Fuks Z. The effect of radiation on prostacyclin (PGI2) production by cultured endothelial cells. Prostaglandins 1983; 25: 263-79.
• 17 Kaushansky K. Thrombopoietin: more than a lineage-specific megakaryocyte growth factor. Stem Cells 1997; 15 Suppl 1: 97-102.
• 18 Shibuya K, Akahori H, Takahashi K, Tahara E, Kato T, Miyazaki H. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice. Blood 1998; 91: 37-45.
• 19 Wagemaker G, Neelis KJ, Hartong SCC, Wognum AW, Thomas GR, Fielder PJ, Eaton DL. The efficacy of recombinant TPO in murine and nonhuman primate models for myelosuppression and stem cell transplantation. Stem Cells 1998; 16: 127-41.
• 20 Mouthon MA, Van der Meeren A, Gaugler MH, Visser TP, Squiban C, Gourmelon P, Wagemaker G. Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body irradiation. Int J Radiat Oncol Biol Phys 1999; 43: 867-75.
• 21 Broudy VC, Lin NL, Sabath DF, Papayannopoulou T, Kaushansky K. Human platelets display high-affinity receptors for thrombopoietin. Blood 1997; 89: 1896-904.
• 22 Chen J, Herceg-Harjacek L, Groopman JE, Grabarek J. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood 1995; 86: 4054-62.
• 23 Kojima H, Hamazaki Y, Nagata Y, Todokoro K, Nagasawa T, Abe T. Modulation of platelet activation in vitro by thrombopoietin. Thromb Haemost 1995; 74: 1541-5.
• 24 Toombs CF, Young CH, Glaspy JA, Varnum BC. Megakaryocyte growth and development factor (MGDF) moderately enhances in vitro platelet aggregation. Thromb Res 1995; 80: 23-33.
• 25 Montrucchio G, Brizzi MF, Calosso G, Marengo S, Pegoraro L, Camussi G. Effects of recombinant human megakaryocyte growth and development factor on platelet activation. Blood 1996; 87: 2762-8.
• 26 Oda A, Miyakawa Y, Druker BJ, Ozaki K, Yabusaki K, Shirasawa Y, Handa M, Kato T, Miyazaki H, Shimosaka A, Ikeda Y. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood 1996; 87: 4664-70.
• 27 Harker LA, Hunt P, Marzec UM, Kelly AB, Tomer A, Hanson SR, Stead RB. Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. Blood 1996; 87: 1833-44.
• 28 Harker LA, Marzec UM, Hunt P, Kelly AB, Tomer A, Cheung E, Hanson SR, Stead RB. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood 1996; 88: 511-21.
• 29 Toombs CF. The effect of MGDF on platelet function and thrombosis in animal models. Stem Cells 1998; 16: 121-6.
• 30 Mouthon M-A, Gaugler M-H, Van der Meeren A, Vandamme M, Gourmelon P, Wagemaker G. Single administration of thrombopoietin to lethally irradiated mice prevents the infectious and thrombotic events leading to mortality. Exp Hematol 2001; 29: 30-40.
• 31 Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Thromb Vasc Biol 1999; 19: 2281-5.
• 32 Lijnen HR, van Hoef B, Beelen V, Collen D. Characterization of the murine plasma fibrinolytic system. Eur J Biochem 1994; 224: 863-71.
• 33 Healy AM, Hancock WW, Christie PD, Rayburn HB, Rosenberg RD. Intravascular coagulation activation in a murine model of thrombomodulin deficiency: effects of lesion size, age, and hypoxia on fibrin deposition. Blood 1998; 92: 4188-97.
• 34 Nishiyama U, Morita H, Torii Y, Kuwaki T, Shimizu E, Akahori H, Kato T, Miyazaki H. Platelets exposed to elevated levels of endogenous thrombopoietin in vivo have a reduced response to megakaryocyte growth and development factor in vitro. Thromb Haemost 2001; 85: 152-9.
• 35 Nishiyama U, Akahori H, Kuwaki T, Miyazaki H. In vivo effect of thombopoietin on thrombus formation in rats. Abstract from XVIII Congress of the International Society on Thrombosis and Haemostasis; Paris; France: July 2001..
• 36 Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999; 100: 1667-72.
• 37 Ashida S, Sakuma K, Abiko Y. Antithrombotic effects of ticlopidine, acetylsalicyclic acid and dipyridamole in vascular shunt model in rats. Thromb Res 1980; 17: 663-71.
• 38 Morishita K, Wada M, Kumada T, Tanaka T, Tomikawa M, Iwamoto M. Effect of ticlopidine and other antithrombotics on the venous thrombosis induced by endothelial damage of jugular vein in rats. Thromb Res 1991; 63: 373-84.
• 39 Umemura K, Ishihara H, Nakashima M. Anti-platelet effects of clopidogrel in rat middle cerebral artery thrombosis model. Thromb Res 1995; 80: 209-16.